Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

Delayed Data
As of Feb 12
 0.0001 / +0.03%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Its most advance product candidate, is the subject of SEAMLESS, a phase 3 trail being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia in the elderly, and other studies for myelodysplastic syndromes, chronic lymphocytic leukemia and solid tumors, including breast, lung, ovarian and pancreatic cancer and in particular those carrying BRCA mutations. The company's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Cyclacel Pharmaceuticals was founded by Ronald J. Berenson, David P. Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Contact Information

Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Berkeley Heights New Jersey 07922-2811
P:(908) 517-7330
Investor Relations:



Other institutional22.11%
Mutual fund holders2.93%
Individual stakeholders1.12%

Top Executives

Spiro RombotisPresident, Chief Executive Officer & Director
Paul McBarronCOO, CFO, Secretary, Director & Executive VP
David GloverChief Scientist
Susan DavisDirector-Business Development
Bill HarrisCorporate Controller